comparemela.com

Latest Breaking News On - Antiangiogenesis - Page 1 : comparemela.com

For Retina Specialists, 2024 Is a Time to Try New Tools

This is a year for ophthalmologists to get acclimated with three blockbuster retina drugs approved in 2023, get reacclimated with a returning implant, and to brace for 2025 and beyond.

United statesWest virginiaIveric bioAbbvie allerganGenentech rochePegcetacoplan syfovreReginal sandersSamsung bioepisDavid boyerLos angelesRetina societyJanssen pharmaceuticalsAmerican society of retina specialistDrug administrationEyepoint pharmaceuticalsRegeneron pharmaceuticals

Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC

A new study showed improved progression-free survival when systemic therapy is added to TACE for HCC. Overall survival outcomes are pending.

United statesNew yorkJosep llovetRiccardo lencioniUniversity of pisaAmerican society of clinical oncologyAmerican societyClinical oncologyMount sinai hospitalHepatocellular carcinoma hcc liver cancer of theAngiogenesis inhibitorHumanized monoclonal antibodyRastuzumab humanised monoclonal antibodyBiologic therapyVascular endothelial growth factor

ADC Shows Survival Benefit in Mets Cervical Cancer

The antibody-drug conjugate tisotumab vedotin led to improved outcomes compared with chemotherapy in second- or third-line treatment of recurrent/metastatic cervical cancer.

United statesKrishnansu tewariEuropean society of medical oncologyUniversity of californiaEuropean societyMedical oncologyCervical cancerAlignant cervix neoplasmBiologic therapyAlignant neoplasiaSkin cancerAlignant skin neoplasmSquamous carcinomaBasal cell carcinomaAsal cell carcinoma of the skinAntibody drug conjugates adcs

Compass Therapeutics to Participate in Upcoming Investor

BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company.

United statesNew yorkDanna giffordCompass therapeutics incAnnual biopharma conferenceAnnual global investment conferenceFireside chatCompass therapeuticsNasdaq cmpxCompass therapeuticsImmuno oncology

FDA OKs Trifluridine/Tipiracil Plus Bevacizumab for mCRC

FDA OKs Trifluridine/Tipiracil Plus Bevacizumab for mCRC
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaJosep taberneroDrug administrationHebron university hospitalTaiho oncologyColorectal cancerBiologic therapyAngiogenesis inhibitorNhibitor angiogenesis Humanized monoclonal antibodyNoncolorectal gastrointestinal cancerOncolorectal gi cancerAbdominal painPain managementPain managementAdenocarcinoma gastroesophageal junction

vimarsana © 2020. All Rights Reserved.